New oral heart failure drug appears to be safe and well tolerated in 58-patient early clinical trial
AI Summary
An early clinical trial involving 58 patients has shown that a new oral drug for chronic heart failure is safe and well tolerated. The study was conducted by researchers from Karolinska Institutet and published in The Lancet.
An early clinical study shows that a new oral drug is safe and well tolerated in patients with chronic heart failure. The study, led by researchers at Karolinska Institutet, has been published in The Lancet.
Health oral drug heart failure clinical trial Karolinska Institutet The Lancet patient safety medical research